Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Review

The application of plant-exosome-like nanovesicles as improved drug delivery systems for cancer vaccines

Author: Tatiana Hillman

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

The use of cancer immunotherapeutics is currently increasing. Cancer vaccines, as a form of immunotherapy, are gaining much attention in the medical community since specific tumor-antigens can activate immune cells to induce an anti-tumor immune response. However, the delivery of cancer vaccines presents many issues for research scientists when designing cancer treatments and requires further investigation. Nanoparticles, synthetic liposomes, bacterial vectors, viral particles, and mammalian exosomes have delivered cancer vaccines. In contrast, the use of many of these nanotechnologies produces many issues of cytotoxicity, immunogenicity, and rapid clearance by the mononuclear phagocyte system (MPS). Plant-exosome-like nanovesicles (PELNVs) can provide solutions for many of these challenges because they are innocuous and nonimmunogenic when delivering nanomedicines. Hence, this review will describe the potential use of PELNVs to deliver cancer vaccines. In this review, different approaches of cancer vaccine delivery will be detailed, the mechanism of oral vaccination for delivering cancer vaccines will be described, and the review will discuss the use of PELNVs as improved drug delivery systems for cancer vaccines via oral administration while also addressing the subsequent challenges for advancing their usage into the clinical setting.
Literature
1.
2.
3.
4.
5.
M. Saxena, S. H. van der Burg, C. J. M. Melief and N. Bhardwaj. Nat Rev Cancer. 2021, 21; 360–378 647
6.
7.
8.
Saxena M, van der Burg SH, Melief CJ, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78.PubMedCrossRef
9.
10.
Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano‐platforms for cancer vaccine development. In Exploration. 2023, p. 20210263.
11.
Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New Eng J Med. 2009;361(19):1838–47.PubMedCrossRef
12.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y. Sipuleucel-T immunotherapy for castration- resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.PubMedCrossRef
13.
Neller MA, Alejandro Lopez J, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol. 2008;20(5):286–95.PubMedCrossRef
14.
Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39(14):14–21.PubMedCrossRef
15.
Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, et al. Peptide– TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38(3):320–32.PubMedPubMedCentralCrossRef
16.
van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219–33.PubMedCrossRef
17.
Wang J, Zhu M, Nie G. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev. 2021;178(113974): 113974.PubMedCrossRef
18.
Nie G, Zhu M, Zhao XL, Nie G. Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. Adv Drug Delivery Rev. 2021;176(113889):113889–9.
19.
Du G, Sun X. Current advances in sustained release microneedles. Pharm Fronts. 2020;02(01):11–22.CrossRef
20.
Deng H, Song K, Zhao X, Li Y, Wang F, Zhang J, et al. Tumor microenvironment activated membrane fusogenic liposome with speedy antibody and doxorubicin delivery for synergistic treatment of metastatic tumors. ACS Appl Mater Interfaces. 2017;9(11):9315–26.PubMedCrossRef
21.
Sun L, Gao Y, Wang Y, Wei Q, Shi J, Chen N, et al. Guiding protein delivery into live cells using DNA-programmed membrane fusion. Chem Sci. 2018;9(27):5967–75.PubMedPubMedCentralCrossRef
22.
Dutta DK, Pulsipher A, Luo W, Mak H, Yousaf MN. Engineering cell surfaces via liposome fusion. Bioconjugate Chem. 2011;22(12):2423–33.CrossRef
23.
Kunisawa J. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Deliv Rev. 2001;52(3):177–86.PubMedCrossRef
24.
Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proceedings of the National Academy of Sciences of the United States of America. 2021; 118(6).
25.
26.
Krishnan N, Kubiatowicz LJ, Holay M, Zhou J, Fang RH, Zhang L. Bacterial membrane vesicles for vaccine applications. Adv Drug Deliv Rev. 2022;185(114294): 114294.PubMedCrossRef
27.
Ma XY, Hill BD, Hoang T, Wen F. Virus-inspired strategies for cancer therapy. Sem Cancer Biol. 2021;86:1143.CrossRef
28.
29.
Marasini N, Skwarczynski M, Toth I. Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines. 2014;13:1361–76.PubMedCrossRef
30.
Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, Smart S, Sovran J, Stephens D, Katz J. Survey of the prevalence of immunization noncompliance due to needle fears in children and adults. Vaccine. 2012;30:4807–12.PubMedCrossRef
31.
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger JA. Vaccine hesitancy: an overview. Hum Vaccines Immunother. 2013;9:1763–73.CrossRef
32.
Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. Wien Klin Wochenschr. 2021;133:931–41.PubMedPubMedCentralCrossRef
33.
Dad HA, Gu TW, Zhu AQ, Huang LQ, Peng LH. Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms. Mol Ther. 2021;29(1):13–31.PubMedCrossRef
34.
Zhuang X, Teng Y, Samykutty A, Mu J, Deng Z, Zhang L, Cao P, Rong Y, Yan J, Miller D, Zhang HG. Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol Ther. 2016;24:96–105.PubMedCrossRef
35.
Song Y, Wu Y, Xu L, Jiang T, Tang C, Yin C. Caveolae- mediated endocytosis drives robusts iRNA delivery of polymeric nanoparticles to macrophages. ACS Nano. 2021;15:8267–82.PubMedCrossRef
36.
Fan W, Xia D, Zhu Q, Li X, He S, Zhu C, Guo S, Hovgaard L, Yang M, Gan Y. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oralinsulin delivery. Biomaterials. 2018;151:13–23.PubMedCrossRef
37.
Park J, Choi JU, Kim K, Byun Y. Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex. Biomaterials. 2017;147:145–54.PubMedCrossRef
38.
Ding Y, Li Z, Jaklenec A, Hu Q. Vaccine delivery systems toward lymph nodes. Adv Drug Deliv Rev. 2021;1(179): 113914.CrossRef
39.
Jiang H, Wang Q, Sun X. Lymph node targeting strategies to improve vaccination efficacy. J Control Release. 2017;10(267):47–56.CrossRef
40.
Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7:790–802.PubMedCrossRef
41.
Zhang L, Wu S, Qin Y, Fan F, Zhang Z, Huang C, Ji W, Lu L, Wang C, Sun H, Leng X. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy. Nano Lett. 2019;19(7):4237–49.PubMedCrossRef
42.
Wang H, Sobral MC, Zhang D, Cartwright ANR, Li AW, Dellacherie MO, et al. Metabolic labeling and targeted modulation of dendritic cells. Nat Mater. 2020;19(11):1244–52.PubMedPubMedCentralCrossRef
43.
Qin H, Zhao R, Qin Y, Zhu J, Chen LQ, Di C, et al. Development of a cancer vaccine using in vivo click-chemistry-mediated active lymph node accumulation for improved immunotherapy. Adv Mater. 2021;33(20):2006007–17.CrossRef
44.
45.
Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–22.PubMedPubMedCentralCrossRef
46.
Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR–T-cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162–8.PubMedPubMedCentralCrossRef
47.
48.
Patil AA, Rhee WJ. Exosomes: biogenesis, composition, functions, and their role in premetastatic niche formation. Biotechnol Bioprocess Eng. 2019;24:689–701.CrossRef
49.
Colombo M, Moita C, Van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Théry C, Raposo G. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126:5553–65.PubMed
50.
Xu J, Camfeld R, Gorski SM. The interplay between exosomes and autophagy–partners in crime. J Cell Sci. 2018;131:jcs215210.PubMedCrossRef
51.
Xing H, Tan J, Miao Y, Lv Y, Zhang Q. Crosstalk between exosomes and autophagy: a review of molecular mechanisms and therapies. J Cell Mol Med. 2021;25:2297–308.PubMedPubMedCentralCrossRef
52.
Blanc L, Vidal M. New insights into the function of Rab GTPases in the context of exosomal secretion. Small GTPases. 2018;9:95–106.PubMedCrossRef
53.
54.
Hassanpour M, Rezaie J, Darabi M, Hiradfar A, Rahbarghazi R, Nouri M. Autophagy modulation altered diferentiation capacity of CD146+ cells toward endothelial cells, pericytes, and cardiomyocytes. Stem Cell Res Ther. 2020;11:1–14.CrossRef
55.
Abdyazdani N, Nourazarian A, Charoudeh HN, Kazemi M, Feizy N, Akbarzade M, Mehdizadeh A, Rezaie J, Rahbarghazi R. The role of morphine on rat neural stem cells viability, neuro-angiogenesis and neuro-steroidgenesis properties. Neurosci Lett. 2017;636:205–12.PubMedCrossRef
56.
Mulcahy LA, Pink RC, Carter DRF. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3:24641.CrossRef
57.
58.
Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signaling. Cell Commun Signal. 2021;19:1–19.CrossRef
59.
Dominkuš PP, Stenovec M, Sitar S, Lasič E, Zorec R, Plemenitaš A, Žagar E, Kreft M, Lenassi M. PKH26 labeling of extracellular vesicles characterization and cellular internalization of contaminating PKH26 nanoparticles. Biochim et Biophys Acta BBA Biomembr. 2018;1860:1350–61.CrossRef
60.
Mendt M, Rezvani K, Shpall E. Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant. 2019;54:789–92.PubMedCrossRef
61.
62.
Bunggulawa EJ, Wang W, Yin T, Wang N, Durkan C, Wang Y, Wang G. Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnol. 2018;16:1–13.CrossRef
63.
Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specifcities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21:9–17.PubMedCrossRef
64.
Hoppstädter J, Dembek A, Linnenberger R, Dahlem C, Barghash A, Fecher-Trost C, Fuhrmann G, Koch M, Kraegeloh A, Huwer H. Toll-like receptor 2 release by macrophages: an anti-infammatory program induced by glucocorticoids and lipopolysaccharide. Front Immunol. 2019;10:1634.PubMedPubMedCentralCrossRef
65.
Kooijmans SAA, Fliervoet LAL, Van Der Meel R, Fens MHAM, Heijnen HFG, Henegouwen PVB, Vader PCVV, Schifelers RM. PEGylated and targeted extracellular vesicles display enhanced cell specifcity and circulation time. J Control Release. 2016;224:77–85.PubMedCrossRef
66.
67.
Nunes, S.S., Fernandes, R.S., Cavalcante, C.H., da Costa César, I., Leite, E.A., Lopes, S.C.A., Ferretti, A., Rubello, D., Townsend, D.M., de Oliveira, M.C., et al. Influence of PEG coating on the biodistribution and tumor accumulation of pH valuesensitive liposomes. Drug Deliv Transl Res. 2019; 9: 123–130.
68.
Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG- conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–23.PubMedCrossRef
69.
Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172:38–47.PubMedCrossRef
70.
Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):148–56.PubMedCrossRef
71.
Rupert DLM, Claudio V, Lässer C, and Bally M. Methods for the physical characterization and quantification of extracellular vesicles in biological samples. Biochim. Biophys. Acta, Gen. Subj. 2017, 1861 (1 Pt A), 3164–3179.
72.
Smyth TJ, Redzic JS, Graner MW, Anchordoquy TJ. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim Biophys Acta. 2014;1838:2954–65.PubMedPubMedCentralCrossRef
73.
Schuh CMAP, Cuenca J, Alcayaga-Miranda F, Khoury M. Exosomes on the border of species and kingdom intercommunication. Transl Res. 2019;210:80–98.PubMedCrossRef
74.
Wang Q, Zhuang X, Mu J, Deng Z-B, Jiang H, Zhang L, Xiang X, Wang B, Yan J, Miller D, Zhang HG. Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun. 1867;2013:4.
75.
Wang Q, Ren Y, Mu J, Egilmez NK, Zhuang X, Deng Z, Zhang L, Yan J, Miller D, Zhang HG. Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites. Cancer Res. 2015;75:2520–9.PubMedPubMedCentralCrossRef
76.
Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B, Zhang L, et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol Ther. 2013;21:1345–57.PubMedPubMedCentralCrossRef
77.
78.
Feng J, Xiu Q, Huang Y, et al. Plant derived vesicle-like nanoparticles as promising biotherapeutic tools: present and future. In: Advanced Materials. 2023. p. e2207826. 10.1002/ adma.202207826.
79.
Wang B, Zhuang X, Deng Z-B, et al. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther. 2014;22:522–34.PubMedPubMedCentralCrossRef
80.
Di Gioia S, Hossain MN, Conese M. Biological properties and therapeutic effects of plant-derived nanovesicles. Open Med. 2020;15:1096–122.CrossRef
81.
Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG. A novel nanoparticle drug delivery system: the anti- inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18:1606–14.PubMedPubMedCentralCrossRef
82.
Shandilya S, Rani P, Onteru SK, Singh D. Small interfering RNA in milk exosomes is resistant to digestion and crosses the intestinal barrier in vitro. J Agric Food Chem. 2017;65:9506–13.PubMedCrossRef
83.
Osteikoetxea X, Sódar B, Németh A, Szabó-Taylor K, Pálóczi K, Vukman KV, Tamási V, Balogh A, Kittel Á, Pállinger É, Buzás EI. Differential detergent sensitivity of extracellular vesicle subpopulations. Org Biomol Chem. 2015;13:9775–82.PubMedCrossRef
84.
Wang B, Zhuang X, Deng Z-B, Jiang H, Mu J, Wang Q, Xiang X, Guo H, Zhang L, Dryden G, et al. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther. 2014;22:522–34.PubMedPubMedCentralCrossRef
85.
Marchant R, Robards A. Membrane systems associated with the plasmalemma of plant cells. Ann Bot. 1968;32:457–71.CrossRef
86.
Halperin W, Jensen WA. Ultrastructural changes during growth and embryogenesis in carrot cell cultures. J Ultrastruct Res. 1967;18:428–43.PubMedCrossRef
87.
McMullen C, Gardner W, Myers G. Ultrastructure of cell-wall thickenings and paramural bodies induced by barley stripe mosaic virus. Phytopathology. 1977;67:462–7.CrossRef
88.
Chafe SC. Cell wall structure in the xylem parenchyma of Cryptomeria. Protoplasma. 1974;81(63–76):89.
89.
Robards A, Kidwai P. Vesicular involvement in differentiating plant vascular cells. New Phytol. 1969;68:343–9.CrossRef
90.
91.
Pérez-Bermúdez P, Blesa J, Soriano JM, Marcilla A. Extracellular vesicles in food: experimental evidence of their secretion in grape fruits. Eur J Pharm Sci. 2017;98:40–50.PubMedCrossRef
92.
Pocsfalvi G, Turiák L, Ambrosone A, Del Gaudio P, Puska G, Fiume I, Silvestre T, Vékey K. Protein biocargo of citrus fruit-derived vesicles reveals heterogeneous transport and extracellular vesicle populations. J Plant Physiol. 2018;229:111–21.PubMedCrossRef
93.
Xiao J, Feng S, Wang X, Long K, Luo Y, Wang Y, Ma J, Tang Q, Jin L, Li X, Li M. Identification of exosome-like nanoparticle-derived microRNAs from 11 edible fruits and vegetables. PeerJ. 2018;6: e5186.PubMedPubMedCentralCrossRef
94.
Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-‘t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C et al. 2013. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2: 20360.
95.
96.
Théry C, Amigorena S, Raposo G, and Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, 30, 3.22.21–3.22.29.
97.
98.
99.
Gardiner C, Di Vizio D, Sahoo S, Théry C, Witwer KW, Wauben M, Hill AF. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracell Vesicles. 2016;5:32945.PubMedCrossRef
100.
van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release. 2014;2014(195):72–85.CrossRef
101.
Loureiro JA, Andrade S, Duarte A, Neves AR, Queiroz JF, Nunes C, Sevin E, Fenart L, Gosselet F, Coelho MA, Pereira MC. Resveratrol and grape extract- loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules. 2017;22:277.PubMedPubMedCentralCrossRef
102.
Wang X, Devaiah SP, Zhang W, Welti R. Signaling functions of phosphatidic acid. Prog Lipid Res. 2006;45:250–78.PubMedCrossRef
103.
104.
105.
Li Z, Wang H, Yin H, Bennett C, Zhang HG, Guo P. Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression. Sci Rep. 2018;8:14644.PubMedPubMedCentralCrossRef
106.
György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol. 2015;55:439–64.PubMedCrossRef
107.
Vashisht M, Rani P, Onteru SK, Singh D. Curcumin encapsulated in milk exosomes resists human digestion and possesses enhanced intestinal permeability in vitro. Appl Biochem Biotechnol. 2017;183:993–1007.PubMedCrossRef
108.
Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38:754–63.PubMedPubMedCentralCrossRef
109.
Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015;205:35–44.PubMedCrossRef
110.
Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E, Xu C, Merlin D. Edible ginger-derived nanolipids loaded with doxorubicin as a novel drug- delivery approach for colon cancer therapy. Mol Ther. 2016;24:1783–96.PubMedPubMedCentralCrossRef
111.
Zhang M, Wang X, Han MK, Collins JF, Merlin D. Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine. 2017;12:1927–43.PubMedPubMedCentralCrossRef
112.
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–5.PubMedCrossRef
113.
Wahlgren J, Karlson TD, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, Valadi H. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012;40:e130.PubMedPubMedCentralCrossRef
114.
Lamichhane TN, Raiker RS, Jay SM. Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Mol Pharm. 2015;12:3650–7.PubMedPubMedCentralCrossRef
115.
Donoso-Quezada J, Ayala-Mar S, González-Valdez J. State-of-the-art exosome loading and functionalization techniques for enhanced therapeutics: a review. Crit Rev Biotechnol. 2020;40(804–820):116.
116.
Smyth T, Petrova K, Payton NM, Persaud I, Redzic JS, Graner MW, SmithJones P, Anchordoquy TJ. Surface functionalization of exosomes using click chemistry. Bioconjug Chem. 2014;25:1777–84.PubMedPubMedCentralCrossRef
117.
Collins NC, Thordal-Christensen H, Lipka V, Bau S, Kombrink E, Qiu JL, Hückelhoven R, Stein M, Freialdenhoven A, Somerville SC, Schulze-Lefert P. SNARE-protein-mediated disease resistance at the plant cell wall. Nature. 2003;425:973–7.PubMedCrossRef
118.
Ramirez JEV, Sharpe L, Peppas N. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116–31.CrossRef
119.
120.
Afrin H, Geetha Bai R, Kumar R, Ahmad SS, Agarwal SK, Nurunnabi M. Oral delivery of RNAi for cancer therapy. Cancer Metastasis Rev. 2023;42:1–26.CrossRef
121.
Weng Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37:801–25.PubMedCrossRef
122.
Blythe, R. H. Sympathomimetic preparation. Google Patents. 1956
123.
Barenholz YC. Doxil®—The frst FDA-approved nanodrug: lessons learned. J Control Release. 2012;160(2):117–34.PubMedCrossRef
124.
125.
126.
Jones DH, Corris S, McDonald S, Clegg JCS, Farrar GH. Poly (DL- lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 1997;15(8):814–7.PubMedCrossRef
127.
128.
129.
130.
Kunisawa J, Kurashima Y, Kiyono H. Gut-associated lymphoid tissues for the development of oral vaccines. Adv Drug Del Rev. 2012;64:523–30.CrossRef
131.
Kim KS, Suzuki K, Cho H, Youn YS, Bae YH. Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport. ACS Nano. 2018;12:8893–900.PubMedPubMedCentralCrossRef
132.
Qi J, Zhuang J, Lv Y, Lu Y, Wu W. Exploiting or overcoming the dome trap for enhanced oral immunization and drug delivery. J Controlled Release. 2018;275:92–106.CrossRef
133.
He C, Yin L, Tang C, Yin C. Multifunctional polymeric nanoparticles for oral delivery of TNF-Alphas iRNA to macrophages. Biomaterials. 2013;34:2843–54.PubMedCrossRef
134.
Susa F, Limongi T, Dumontel B, Vighetto V, Cauda V. Engineered extracellular vesicles as a reliable tool in cancer nanomedicine. Cancers. 1979;2019:11.
135.
Amaro MI, Rocha J, Vila-Real H, Eduardo-Figueira M, Mota-Filipe H, Sepodes B, et al. Anti-inflammatory activity of naringin and the biosynthesized naringenin by naringinase immobilized in microstructured materials in a model of DSS-induced colitis in mice. Food Res Int. 2009;42:1010–7.CrossRef
136.
Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, Wei X, Chou G, Wang ZT, Mani S. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-kB signaling. Br J Nutr. 2013;110:599–608.PubMedPubMedCentralCrossRef
137.
Zhang H, Kuang H. Intelligent oral tumor vaccines for cancer therapy. Matter. 2022;5(8):2476–8.CrossRef
138.
139.
140.
141.
Ortega A, Martinez-Arroyo O, Forner MJ, et al. Exosomes as drug delivery systems: endogenous nanovehicles for treatment of systemic lupus erythematosus. Pharmaceutics. 2020;13:3.PubMedPubMedCentralCrossRef
142.
Tsai SJ, Atai NA, Cacciottolo M, et al. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. J Biol Chem. 2021;297: 101266.PubMedPubMedCentralCrossRef
143.
Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18:1606–14.PubMedPubMedCentralCrossRef
144.
Choi H, Kim M-Y, Kim D-H, et al. Quantitative biodistribution and pharmacokinetics study of GMP-grade exosomes labeled with 89Zr radioisotope in mice and rats. Pharmaceutics. 2022;14:1118.PubMedPubMedCentralCrossRef
145.
Cong M, Tan S, Li S, et al. Technology insight: plant-derived vesicles-How far from the clinical biotherapeutics and therapeutic drug carriers? Adv Drug Deliv Rev. 2022;182: 114108.PubMedCrossRef
146.
147.
Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, Han MK, Xiao B, Xu C, Srinivasan S, Merlin D. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321–40.PubMedPubMedCentralCrossRef
148.
Raimondo S, Naselli F, Fontana S, Monteleone F, Lo Dico A, Saieva L, Zito G, Flugy A, Manno M, Di Bella MA, et al. Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. Oncotarget. 2015;6:19514–27.PubMedPubMedCentralCrossRef
149.
150.
Tran T-H, Mattheolabakis G, Aldawsari H, Amiji M. Exosomes as nanocarriers for immunotherapy of cancer and infammatory diseases. Clin Immunol. 2015;160:46–58.PubMedCrossRef
151.
Mignot G, Roux S, Thery C, Ségura E, Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med. 2006;10:376–88.PubMedCrossRef
152.
Galbo PM Jr, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017;8: 114722.PubMedPubMedCentralCrossRef
153.
Sharma A, Johnson A. Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker. J Cell Physiol. 2020;235:1921–32.PubMedCrossRef
154.
Bell BM, Kirk ID, Hiltbrunner S, Gabrielsson S, Bultema JJ. Designer exosomes as next-generation cancer immunotherapy. Nanomed Nanotechnol Biol Med. 2016;12:163–9.CrossRef
155.
Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefrst phase I clinical trial. J Transl Med. 2005;3:1–13.CrossRef
156.
Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:1–8.CrossRef
157.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A. Dendritic cell-derived exosomes as maintenance immunotherapy after frst line chemotherapy in NSCLC. Oncoimmunology. 2016;5: e1071008.PubMedCrossRef
158.
Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Can Res. 2014;74:6060–70.CrossRef
159.
Patel GK, Khan MA, Zubair H, Srivastava SK, Khushman M, Singh S, Singh AP. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci Rep. 2019;9:1–10.CrossRef
160.
He L, Zhu D, Wang J, Wu X. A highly efcient method for isolating urinary exosomes. Int J Mol Med. 2019;43:83–90.PubMed
161.
Sadeghi S, Tehrani FR, Tahmasebi S, Shafiee A, Hashemi SM. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023;31:145–69.PubMedPubMedCentralCrossRef
162.
Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, Delcayre A, Le Pecq JB, Combadière B, Amigorena S, et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res. 2008;68:1228–35.PubMedCrossRef
163.
Yang C, Zhang M, Merlin D. Advances in plant-derived edible nanoparticle- based lipid nanodrug delivery systems as therapeutic nanomedicines. J Mater Chem B. 2018;6:1312–21.PubMedPubMedCentralCrossRef
164.
Huang Y, Wag S, Cai Q, Jin H. Effective methods for isolation and purification of extracellular vesicles from plants. J Integr Plant Biol. 2021;63(2020–1058):2030.
165.
Ipinmoroti AO, Turner J, Bellenger EJ, Crenshaw BJ, Xu J, Reeves C, Ajayi O, Li T, Matthews QL. Characterization of cannabis strain-plant-derived extracellular vesicles as potential biomarkers. Protoplasma. 2023;2023:12.
166.
Pomatto MA, Gai C, Negro F, Massari L, Deregibus MC, De Rosa FG, Camussi G. Oral delivery of mRNA vaccine by plant-derived extracellular vesicle carriers. Cells. 2023;12(14):1826.PubMedPubMedCentralCrossRef
167.
Pomatto MAC, Gai C, Negro F, Massari L, Deregibus MC, Grange C, De Rosa FG, Camussi G. Plant-derived extracellular vesicles as a delivery platform for RNA-based vaccine: feasibility study of an oral and intranasal SARS-CoV-2 vaccine. Pharmaceutics. 2023;15:974.PubMedPubMedCentralCrossRef
168.
Tsai SJ, Atai NA, Cacciottolo M, Nice J, Salehi A, Guo C, Sedgwick A, Kanagavelu S, Gould SJ. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. J Biol Chem. 2021;297: 101266.PubMedPubMedCentralCrossRef
169.
Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14:667–85.PubMedCrossRef
170.
Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6:148–58.PubMedCrossRef
171.
Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun. 1999;6:2884–90.CrossRef
172.
Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol. 2002;169:566–74.PubMedCrossRef
173.
Atalis A, Keenum MC, Pandey B, Beach A, Pradhan P, Vantucci C, O’Farrell L, Noel R, Jain R, Hosten J, et al. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine. J Control Release Off J Control Release Soc. 2022;347:476–88.CrossRef
174.
Lapuente D, Fuchs J, Willar J, Vieira Antão A, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS, et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. 2021;12:6871.PubMedPubMedCentralCrossRef
175.
176.
Umezu T, Takanashi M, Murakami Y, et al. Acerola exosome-like nanovesicles to systemically deliver nucleic acid medicine via oral administration. Mol Ther Methods Clin Dev. 2021;21:199–208.PubMedPubMedCentralCrossRef
177.
Zeng L, Wang H, Shi W, et al. Aloe derived nanovesicle as a functional carrier for indocyanine green encapsulation and phototherapy. J Nanobiotechnol. 2021;19:439.CrossRef
178.
You JY, Kang SJ, Rhee WJ. Isolation of cabbage exosome-like nanovesicles and investigation of their biological activities in human cells. Bioact Mater. 2021;6:4321–32.PubMedPubMedCentral
179.
Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321–40.PubMedPubMedCentralCrossRef
180.
Zhang M, Wang X, Han MK, et al. Oral administration of gingerderived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine. 2017;12:1927–43.PubMedPubMedCentralCrossRef
181.
Li Z, Wang H, Yin H, et al. Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression. Sci Rep. 2018;8:14644.PubMedPubMedCentralCrossRef
182.
Yang C, Zhang M, Lama S, et al. Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis. J Control Release. 2020;323:293–310.PubMedPubMedCentralCrossRef
183.
Niu W, Xiao Q, Wang X, et al. A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy. Nano Lett. 2021;21:1484–92.PubMedCrossRef
184.
Garaeva L, Kamyshinsky R, Kil Y, et al. Delivery of functional exogenous proteins by plant-derived vesicles to human cells in vitro. Sci Rep. 2021;11:6489.PubMedPubMedCentralCrossRef
185.
Wang Q, Ren Y, Mu J, et al. Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites. Cancer Res. 2015;75:2520–9.PubMedPubMedCentralCrossRef
186.
Zhuang X, Teng Y, Samykutty A, et al. Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol Ther. 2016;24:96–105.PubMedCrossRef
187.
Teng Y, Mu J, Hu X, et al. Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget. 2016;7:25683–97.PubMedPubMedCentralCrossRef
188.
189.
Jr GWD. Phase I clinical trial investigating the ability of plant exosomes to deliver curcumin to normal and malignant colon tissue. clinicaltrials.gov; 2021. Report No.: NCT01294072. https://​clinicaltrials.​gov/​ct2/​ show/NCT01294072. Accessed 1 Sep 2022.
190.
Redman R. Preliminary clinical trial investigating the ability of plant exosomes to abrogate oral mucositis induced by combined chemotherapy and radiation in head and neck cancer patients. clinicaltrials.gov; 2022. Report No.: NCT01668849. https://​clinicaltrials.​gov/​ct2/​show/​ NCT01668849. Accessed 1 Sep 2022.
191.
University of Louisville. A preliminary clinical trial investigating the ability of plant exosomes to mitigate insulin resistance and chronic inflammation in patients diagnosed with polycystic ovary syndrome (PCOS). clinicaltrials.gov; 2021. Report No.: NCT03493984. https://​clinicaltrials.​gov/​ ct2/show/NCT03493984. Accessed 1 Sep 2022.
Metadata
Title
The application of plant-exosome-like nanovesicles as improved drug delivery systems for cancer vaccines
Author
Tatiana Hillman
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00974-6

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue

Analysis

An endothelial-related prognostic index for bladder cancer patients

Analysis

Predicting prostate adenocarcinoma patients’ survival and immune signature: a novel risk model based on telomere-related genes

Research

APOB is a potential prognostic biomarker in hepatocellular carcinoma

Review

Breast cancer cells and adipocytes in hypoxia: metabolism regulation

Research

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

Research

Identification and evaluation of a six-lncRNA prognostic signature for multiple myeloma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits